AssetMark’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.7K Sell
640
-32
-5% -$599 ﹤0.01% 2448
2026
Q2
$12.1K Sell
672
-49
-7% -$927 ﹤0.01% 2382
2026
Q1
$15.7K Sell
721
-30
-4% -$581 ﹤0.01% 2145
2025
Q4
$16.2K Sell
751
-57
-7% -$1.2K ﹤0.01% 2060
2025
Q3
$15.6K Sell
808
-11,865
-94% -$212K ﹤0.01% 1992
2025
Q2
$217K Buy
12,673
+220
+2% +$9.39K ﹤0.01% 1201
2025
Q1
$795K Sell
12,453
-30,306
-71% -$3.19M ﹤0.01% 906
2024
Q4
$5.2M Buy
42,759
+3,734
+10% +$458K 0.01% 492
2024
Q3
$4.87M Buy
39,025
+27,220
+231% +$3.76M 0.01% 455
2024
Q2
$1.87M Buy
11,805
+3,338
+39% +$429K 0.01% 633
2024
Q1
$1.1M Buy
8,467
+1,800
+27% +$220K ﹤0.01% 712
2023
Q4
$643K Buy
6,667
+2,851
+75% +$273K ﹤0.01% 756
2023
Q3
$463K Buy
3,816
+558
+17% +$63.1K ﹤0.01% 769
2023
Q2
$373K Buy
+3,258
New +$420K ﹤0.01% 769

Other funds holding SRPT

AssetMark's SRPT Position: Q3 2026 in Review

AssetMark reduced its Sarepta Therapeutics (SRPT) stake by 4.8% in Q3 2026, selling an estimated $599 and leaving 640 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

AssetMark first reported a position in SRPT in Q2 2023 and has held it in 14 quarters since. The position peaked at $5.2M in Q4 2024. 235 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • AssetMark held 640 shares of Sarepta Therapeutics worth $11.7K as of Q3 2026.
  • AssetMark sold 32 Sarepta Therapeutics shares in Q3 2026, an estimated $599.
  • Sarepta Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2448 holding.
  • AssetMark first reported a position in Sarepta Therapeutics in Q2 2023 and has held it in 14 quarters since.
  • AssetMark's Sarepta Therapeutics position peaked at $5.2M in Q4 2024.
  • 235 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.